Kneat Partners with Pharmaceutical Leader for Digital Transition
Kneat.com, Inc. (TSX: KSI) (OTC: KSIOF), known for its innovative solutions in digitizing validation and quality processes, has achieved a significant milestone. A global pharmaceutical company has entered into a three-year Master Services Agreement with Kneat to transform its validation processes, marking a new era in digital compliance.
About the New Partnership
Based in Germany and employing over 11,000 staff across a multitude of facilities, this renowned company produces a wide range of household consumer health care brands alongside generic and specialty pharmaceuticals, serving clients in more than 120 nations. Following an extensive evaluation process, Kneat emerged as the preferred partner, tasked with modernizing their complex validation procedures worldwide, commencing with Computer System Validation (CSV).
Enhancing Efficiency Through Digital Solutions
Eddie Ryan, the Chief Executive Officer of Kneat, expressed the company's excitement regarding the partnership. He highlighted, "This announcement underscores Kneat’s strong position within the validation landscape. We are eager to assist this organization in streamlining all their validation efforts on a unified platform." This collaboration is aimed at addressing the intricacies of validation in regulated industries, improving both accuracy and compliance.
Kneat's Innovative Solutions
Kneat Solutions is at the forefront of delivering exceptional efficiency in validation and compliance to companies within highly regulated sectors. Its flagship product, Kneat Gx, notably stands out in the industry, acclaimed for its user-friendly features and comprehensive support system, supplemented by an on-demand training academy. The platform is recognized for managing any validation task from start to finish and adheres to stringent regulatory standards, including full ISO 9001 and ISO 27001 certifications, along with 21 CFR Part 11 and Annex 11 compliance. Historical data from multiple independent customer analyses indicate that companies utilizing Kneat Gx have experienced a reduction of 40% or more in validation cycle times, achieved nearly 20% faster market entry, and reduced changeover times by up to 80%.
Understanding the Impact of Digital Validation
The increasing need for efficiency in validation processes within the pharmaceutical sector cannot be overstated. By engaging with Kneat, this global company is set to benefit from a streamlined approach that will not only enhance productivity but also ensure that compliance requirements are consistently met across all operations. The results from the implementation of Kneat Gx are sure to signal a transformation in how validation tasks are conducted, paving the way for enhanced operational integrity and market responsiveness.
Contact Information
For more information about this collaboration or other inquiries, individuals are encouraged to reach out to Kneat’s Investor Relations:
Katie Keita, Kneat Investor Relations
P: +1 902-450-2660
E: investors@kneat.com
Frequently Asked Questions
1. What is Kneat's role in the pharmaceutical partnership?
Kneat has been selected to digitize validation processes for a leading global pharmaceutical company through a three-year Master Services Agreement.
2. What does the company aim to achieve by partnering with Kneat?
The company aims to enhance the efficiency, accuracy, and compliance of its validation processes on a global scale, starting with Computer System Validation.
3. How does Kneat Gx improve validation processes?
Kneat Gx allows for streamlined management of validation tasks, resulting in significantly reduced cycle times and improved compliance with industry standards.
4. Why is digital validation important for pharmaceutical companies?
Digital validation is crucial for ensuring operational efficiency and compliance with regulatory requirements, leading to faster market entry and enhanced product integrity.
5. Where can I find more information about Kneat Solutions?
Further details can be obtained by contacting Kneat's Investor Relations or visiting their website.
